Amarin Corp Plc (AMRN)

[jessellivermore]

This is how it works..

NRxs are a measure of new scripts which are written out, or first reach the pharmacy. If they are written on a monthly basis, then each refill is counted as a TRx. If you get a six months script and the six months is over. Then when you get a new script that is a NRx.

Here's the problem.. The cash price (no insurance) for V averages between $230 and $240 for a month supply. The cash price for generic Lovaza averages $270/month. That's right generic Lovaza is more expensive than Vascepa. So why and how do we lose patients to Lovaza? The answer is Vascepa is tier 2 to tier 3, whereas generic Lovaza is tier 1 to tier 2, mainly Tier 1. The tier pricing effects the co-pay, the lower the tier, the lower the co-pay. So even with a coupon the patient could be paying $70 a month for vascepa and only forty dollars for Lovaza. Added to this the pharmacists are incentified to sell generics.

The pharmacist tells the patient they can get the same benefits from Lovaza at half the price. The patient calls the doctors office gets the patient coordinator and she OKs the script change.

Any ideas on how to remedy this situation.

":>) JL